With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine.
FDA
Jul. 16, 2020
NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19
Jun. 24, 2020
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.
Jun. 8, 2020
Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19.
Jun. 1, 2020
Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100.